Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EPS (Basic): 2009-2025

Historic EPS (Basic) for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Sep 2025 value amounting to -$5.08.

  • Madrigal Pharmaceuticals' EPS (Basic) fell 3.25% to -$5.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.89, marking a year-over-year increase of 48.60%. This contributed to the annual value of -$21.90 for FY2024, which is 9.55% down from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' EPS (Basic) is -$5.08, which was down 167.37% from -$1.90 recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' EPS (Basic) registered a high of -$1.90 during Q2 2025, and its lowest value of -$7.38 during Q1 2024.
  • For the 3-year period, Madrigal Pharmaceuticals' EPS (Basic) averaged around -$4.75, with its median value being -$4.92 (2024).
  • Per our database at Business Quant, Madrigal Pharmaceuticals' EPS (Basic) slumped by 74.47% in 2024 and then surged by 73.24% in 2025.
  • Quarterly analysis of 5 years shows Madrigal Pharmaceuticals' EPS (Basic) stood at -$3.78 in 2021, then tumbled by 31.75% to -$4.98 in 2022, then declined by 14.06% to -$5.68 in 2023, then skyrocketed by 54.40% to -$2.59 in 2024, then decreased by 3.25% to -$5.08 in 2025.
  • Its last three reported values are -$5.08 in Q3 2025, -$1.90 for Q2 2025, and -$3.32 during Q1 2025.